Last reviewed · How we verify
lopinavir or efavirenz
Lopinavir is a protease inhibitor that blocks the protease enzyme, preventing viral replication.
Lopinavir is a protease inhibitor that blocks the protease enzyme, preventing viral replication. Used for Treatment of HIV-1 infection in combination with other antiretroviral agents, Prevention of mother-to-child transmission of HIV.
At a glance
| Generic name | lopinavir or efavirenz |
|---|---|
| Also known as | Kaletra, Sustiva |
| Sponsor | French National Agency for Research on AIDS and Viral Hepatitis |
| Drug class | Protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Lopinavir works by binding to the protease enzyme, which is essential for the maturation of viral particles. By inhibiting this enzyme, lopinavir prevents the replication of the virus, thereby reducing the viral load in the body.
Approved indications
- Treatment of HIV-1 infection in combination with other antiretroviral agents
- Prevention of mother-to-child transmission of HIV
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Insomnia
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
- Kuwa Free! - Live Free! (NA)
- Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: